• LAST PRICE
    0.2911
  • TODAY'S CHANGE (%)
    Trending Down-0.0144 (-4.7136%)
  • Bid / Lots
    0.2910/ 5
  • Ask / Lots
    0.2911/ 1
  • Open / Previous Close
    0.3100 / 0.3055
  • Day Range
    Low 0.2911
    High 0.3206
  • 52 Week Range
    Low 0.2900
    High 3.9000
  • Volume
    62,379
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.3064
TimeVolumeASLN
09:32 ET11800.31
09:34 ET5000.3112
09:43 ET2000.310201
09:52 ET12580.31
09:57 ET2000.3206
10:03 ET7000.312749
10:10 ET4530.3055
10:12 ET2000.304
10:17 ET51000.309
10:21 ET22000.3055
10:24 ET8000.3055
10:26 ET148390.3
10:28 ET66990.3
10:32 ET3000.2999
10:44 ET50000.2979
10:46 ET42710.2979
10:48 ET10000.2953
10:50 ET25000.295
10:55 ET1570.2979
11:00 ET10000.2964
11:04 ET2000.2957
11:09 ET4000.2957
11:18 ET1000.2958
11:26 ET102000.295
11:27 ET6000.2911
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesASLN
Aslan Pharmaceuticals Ltd
6.9M
-0.1x
---
United StatesRNAZ
Transcode Therapeutics Inc
6.9M
0.0x
---
United StatesVIRI
Virios Therapeutics Inc
6.9M
-0.9x
---
United StatesENZC
Enzolytics Inc
6.7M
0.0x
---
United StatesNLSP
NLS Pharmaceutics AG
6.7M
-0.5x
---
United StatesGRTX
Galera Therapeutics Inc
7.2M
-0.1x
---
As of 2024-06-26

Company Information

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Contact Information

Headquarters
83 Clemenceau Avenue, #12-03 Ue Square, Singapore 239920
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Andrew Howden
Chief Executive Officer, Director
Carl Firth
Chief Operating Officer, Head of Finance
Kiran Asarpota
General Counsel
Ben Goodger
Chief Business Officer
Stephen Doyle

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.9M
Revenue (TTM)
$12.0M
Shares Outstanding
905.1K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.40
EPS
$-3.01
Book Value
$3.00
P/E Ratio
-0.1x
Price/Sales (TTM)
0.6
Price/Cash Flow (TTM)
---
Operating Margin
-369.02%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.